LANGERHANS CELL HISTIOCYTOSIS
Clinical trials for LANGERHANS CELL HISTIOCYTOSIS explained in plain language.
Never miss a new study
Get alerted when new LANGERHANS CELL HISTIOCYTOSIS trials appear
Sign up with your email to follow new studies for LANGERHANS CELL HISTIOCYTOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Global trial aims to tame rare childhood disease and prevent lasting damage
Disease control OngoingThis study tests different treatment plans for children under 18 with Langerhans cell histiocytosis, a rare disease where immune cells build up and damage tissues. The goal is to control the disease, prevent it from coming back, and reduce long-term problems like hormone issues o…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS
Phase: PHASE2, PHASE3 • Sponsor: North American Consortium for Histiocytosis • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
Experimental drug shows promise for rare immune disorder
Disease control OngoingThis study tested the drug clofarabine in 25 people with Langerhans cell histiocytosis (LCH) or related disorders that had returned or not improved with standard therapy. The goal was to see if the drug could shrink or eliminate disease. Results measured how many patients had the…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Gene test trial aims to personalize cancer care for kids
Knowledge-focused OngoingThis study screens children and young adults (ages 1-21) with advanced solid tumors, lymphomas, or related disorders that have not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be targeted by cert…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 17, 2026 02:15 UTC